GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Rating of "Moderate Buy" by Analysts

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eleven ratings firms that are covering the stock, Marketbeat reports. Five analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $6.55.

Several brokerages have recently weighed in on GDRX. The Goldman Sachs Group dropped their price objective on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Wells Fargo & Company dropped their price objective on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 29th. Truist Financial lowered their price target on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Finally, UBS Group lowered their price target on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th.

GoodRx Stock Performance

NASDAQ GDRX opened at $4.87 on Thursday. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 0.74. The firm's fifty day moving average price is $4.36 and its two-hundred day moving average price is $4.53. GoodRx has a 1 year low of $3.68 and a 1 year high of $9.26. The firm has a market capitalization of $1.74 billion, a P/E ratio of 60.88, a price-to-earnings-growth ratio of 2.15 and a beta of 1.24.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.05. The company had revenue of $202.97 million for the quarter, compared to analyst estimates of $202.25 million. GoodRx had a net margin of 3.57% and a return on equity of 7.85%. The company's revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.08 earnings per share. As a group, research analysts anticipate that GoodRx will post 0.13 EPS for the current year.

Insider Transactions at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total transaction of $51,249.60. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.53% of the stock is owned by insiders.

Institutional Investors Weigh In On GoodRx

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its stake in GoodRx by 9.1% during the fourth quarter. Geode Capital Management LLC now owns 1,071,761 shares of the company's stock worth $4,986,000 after buying an additional 89,032 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of GoodRx during the 4th quarter valued at approximately $358,000. Barclays PLC grew its holdings in shares of GoodRx by 18.4% during the 4th quarter. Barclays PLC now owns 165,928 shares of the company's stock valued at $772,000 after purchasing an additional 25,815 shares during the last quarter. Northern Trust Corp grew its holdings in shares of GoodRx by 13.5% during the 4th quarter. Northern Trust Corp now owns 421,810 shares of the company's stock valued at $1,961,000 after purchasing an additional 50,256 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of GoodRx by 10.1% during the 4th quarter. Bank of New York Mellon Corp now owns 192,612 shares of the company's stock valued at $896,000 after purchasing an additional 17,633 shares during the last quarter. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.